Our Highly Experienced Executive Team has a Proven Track Record of Leadership, Global Registration and Lifecycle Management for Dozens of Biopharmaceutical Products.

Blake Wise
Chief Executive Officer
Mr. Wise became Chief Executive Officer, and joined the Company’s Board of Directors, in January 2018. Mr. Wise joined Achaogen as Chief Operating Officer in 2015 and, in February 2017 he was appointed President and Chief Operating Officer. Prior to Achaogen, Mr. Wise spent 13 years at Genentech, where he established and led the Cross BioOncology franchise as Vice President, Cross BioOncology. In this role, Mr. Wise spearheaded cross-portfolio initiatives designed to drive the $10B US BioOncology business and the company’s long-term oncology strategy. During his time at Genentech, Mr. Wise also held several other leadership positions of increasing responsibility, including Senior Director, Franchise Head and Life Cycle Leader of the Lytics franchise, with overall commercial responsibility for Genentech’s hospital-based Lytics business. He previously served as a Sales Director in BioOncology, Marketing Director in Cystic Fibrosis and Immunology, and Interactive Marketing Director where he built Genentech’s digital marketing capabilities. Prior to joining Genentech in 2002, Mr. Wise worked in consumer marketing, e-commerce and online marketing outside of the healthcare industry in leadership positions at Gap, Inc. and Webvan.
Mr. Wise currently serves on the board of directors of Calithera Biosciences, Inc., a clinical-stage biopharmaceutical company. Mr. Wise received a Bachelor of Arts degree in Business Economics from University of California, Santa Barbara, and a Masters of Business Administration degree from University of California, Berkeley, Haas School of Business.
Liz Bhatt
Chief Operating Officer

Ms. Bhatt became Chief Operating Officer in July 2018. She joined Achaogen as Chief Business Officer in 2017. Ms. Bhatt brings to Achaogen more than 20 years of experience in corporate development and strategy in the biopharmaceutical industry. Most recently, Ms. Bhatt held the position of Vice President, Corporate Development at Gilead Sciences where she was responsible for executing licenses, acquisitions and collaborations across all of Gilead’s therapeutic areas. While at Gilead, she also led long-term global commercial and strategic planning for Gilead’s antiviral and respiratory franchises. Before Gilead, Ms. Bhatt held corporate development and strategy roles at Eli Lilly and Maxygen. Ms. Bhatt earned a B.A. in Chemistry from Pomona College, an M.S. in Biomedical Sciences from the University of California at San Diego, and an M.B.A. from the Kellogg School of Management at Northwestern University.

Janet Dorling
Chief Commercial Officer

Ms. Dorling joined Achaogen as Chief Commercial Officer in 2017. Prior to Achaogen, Ms. Dorling spent 14 years at Genentech and Roche where, as Vice President of Global Product Strategy, Breast Cancer at Roche/Genentech, she was responsible for developing and implementing global commercialization and lifecycle strategies for the Breast Cancer Franchise. Previously, as Vice President of the Lytics Franchise, Ms. Dorling lead hospital-focused Sales and Marketing teams that promoted Activase and Cathflo in the acute care setting. Ms. Dorling also had multiple roles with increasing responsibility in Market Analysis and Strategy in Ophthalmology, Oncology, and ultimately leading multiple functions with portfolio-wide responsibility. Prior to joining Genentech Ms. Dorling had several roles in Business Development at Altus Biologics, DNA Sciences, and Clontech Laboratories. Ms. Dorling has a Bachelor of Arts in Molecular and Cellular Biology from the University of California at Berkeley, a Master's in Science in Pharmacology and Cancer Biology from Duke University, and a Master's in Business Administration from the Haas School of Business at the University of California at Berkeley.

Gary Loeb
General Counsel and Chief Compliance Officer
Mr. Loeb joined Achaogen in 2016 after more than 15 years of legal affairs experience related to intellectual property, corporate governance, compliance, and business development in the biotechnology industry. Most recently, Mr. Loeb has been General Counsel and Corporate Secretary and on the executive team at three life sciences companies, Amyris, Inc., Counsyl, and most recently Sano Intelligence. Previously, Mr. Loeb spent eleven years at Genentech most recently as Vice President, Intellectual Property, where he oversaw 90 employees in the areas of litigation, patent prosecution, corporate records and technology licensing. 
Since 2006, Mr. Loeb has been an adjunct professor at University of San Francisco Law School. He is currently on the Board of Directors for Project Open Hand, a nonprofit organization that provides meals to critically ill neighbors and seniors, and Columbia Law School. Mr. Loeb received a Bachelor of Science degree in Biology and Bachelor of Arts degree in English from Stanford University in California and a Juris Doctor degree from Columbia Law School in New York. He clerked in the Northern District of Texas and, for several years, practiced commercial and intellectual property law in Los Angeles and San Francisco, California.